<?xml version="1.0" encoding="UTF-8"?>
<p>Viral replication may be particularly active during the early phrase of SARS-CoV-2 infection; thus, antiviral therapy could exerts its greatest effects before the illness progresses into the systemic hyperinflammatory stage [
 <xref rid="B122-viruses-12-01039" ref-type="bibr">122</xref>]. Several antiviral drugs (remdesivir, chloroquine, and hydroxychloroquine) have been shown to have an inhibitory effect on controlling viral infection and replication in patients with COVID-19 [
 <xref rid="B123-viruses-12-01039" ref-type="bibr">123</xref>]. Potential drugs may inhibit viral entry and replication via targeting the ACE2 receptor and TMPRSS2, viral membrane fusion and endocytosis, or the 3CLpro activity of SARS-CoV-2 and the RNA-dependent RNA polymerase [
 <xref rid="B124-viruses-12-01039" ref-type="bibr">124</xref>].
</p>
